Globus Medical, Inc.
GMED
$70.59
$0.911.31%
| Weiss Ratings | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | C | |||
| Rating Factors | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.33 | |||
| Price History | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.44% | |||
| 30-Day Total Return | -24.19% | |||
| 60-Day Total Return | -14.35% | |||
| 90-Day Total Return | -4.01% | |||
| Year to Date Total Return | -13.74% | |||
| 1-Year Total Return | 36.09% | |||
| 2-Year Total Return | 34.00% | |||
| 3-Year Total Return | 9.54% | |||
| 5-Year Total Return | 101.34% | |||
| 52-Week High % Change | -26.60% | |||
| 52-Week Low % Change | 41.25% | |||
| Price | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $94.93 | |||
| 52-Week Low Price | $49.33 | |||
| 52-Week Low Price (Date) | May 01, 2024 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.58B | |||
| Enterprise Value | 9.17B | |||
| Price/Earnings (TTM) | 93.23 | |||
| Earnings Per Share (TTM) | 0.75 | |||
| Earnings Per Share Growth | -35.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.86 | |||
| Price/Book (Q) | 2.29 | |||
| Enterprise Value/Revenue (TTM) | 3.64 | |||
| Price | $70.59 | |||
| Enterprise Value/EBITDA (TTM) | 13.28 | |||
| Enterprise Value/EBIT | 21.01 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 139.71M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 610 930 1800 | |||
| Address | 2560 General Armistead Avenue Audubon, PA 19403 | |||
| Website | www.globusmedical.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 17.31% | |||
| Profit Margin | 4.08% | |||
| Management Effectiveness | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.27% | |||
| Return on Equity | 2.52% | |||
| Income Statement | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.52B | |||
| Total Revenue (TTM) | 2.52B | |||
| Revenue Per Share | $18.03 | |||
| Gross Profit (TTM) | 1.70B | |||
| EBITDA (TTM) | 690.20M | |||
| EBIT (TTM) | 436.18M | |||
| Net Income (TTM) | 102.98M | |||
| Net Income Avl. to Common (TTM) | 102.98M | |||
| Total Revenue Growth (Q YOY) | 6.61% | |||
| Earnings Growth (Q YOY) | 76.30% | |||
| EPS Diluted (TTM) | 0.75 | |||
| EPS Diluted Growth (Q YOY) | 82.87% | |||
| Balance Sheet | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 890.06M | |||
| Cash Per Share (Q) | $6.37 | |||
| Total Current Assets (Q) | 2.18B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.18B | |||
| Current Ratio (Q) | 2.544 | |||
| Book Value Per Share (Q) | $30.40 | |||
| Total Assets (Q) | 5.25B | |||
| Total Current Liabilities (Q) | 855.91M | |||
| Total Debt (Q) | 537.72M | |||
| Total Liabilities (Q) | 1.07B | |||
| Total Common Equity (Q) | 4.18B | |||
| Cash Flow | GMED - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -176.05M | |||
| Cash from Financing (TTM) | -27.70M | |||
| Net Change in Cash (TTM) | 317.15M | |||
| Levered Free Cash Flow (TTM) | 594.83M | |||
| Cash from Operations (TTM) | 520.64M | |||
